MONTPELLIER, France --(BUSINESS WIRE)--
DEINOVE (Paris:ALDEI) (Alternext Paris: ALDEI), a biotech company that discovers, develops and produces high-value compounds from rare bacteria, notably from the Deinococcus genus, announces today its provisional financial calendar for 2017*.
|March 30, 2017||Publication of 2016 Annual Results|
|May 16, 2017||Annual Shareholders Meeting, in Paris (11 :00 CET)|
|September 28, 2017||Publication of 2017 First Half Financial Results|
* This financial calendar is for indicative purposes only and the Company could change its publication dates should it deem necessary.
DEINOVE (Alternext Paris: ALDEI) is a biotech company that discovers, develops and produces compounds with industrial value from rare microorganisms, for the healthcare, nutrition and cosmetics markets.
These innovative production methods represent a sustainable and competitive alternative.
For this, DEINOVE relies on two key assets:
- A unique strain bank with 6,000 rare bacteria that have not yet been exploited, mainly of the Deinococcus genus;
- A genetic, metabolic and fermentation engineering platform that enables them to customize these natural micro-factories, transforming them into new industry standards.
Based in Montpellier, DEINOVE employs approximately 50 employees and has nearly 170 international patent applications. The Company has been listed on Alternext since April 2010.
More information on www.deinove.com
(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.